TY - JOUR
T1 - B cell linker protein (BLNK) is a selective target of repression by PAX5-PML protein in the differentiation block that leads to the development of acute lymphoblastic leukemia
AU - Imoto, Naoto
AU - Hayakawa, Fumihiko
AU - Kurahashi, Shingo
AU - Morishita, Takanobu
AU - Kojima, Yuki
AU - Yasuda, Takahiko
AU - Sugimoto, Keiki
AU - Tsuzuki, Shinobu
AU - Naoe, Tomoki
AU - Kiyoi, Hitoshi
N1 - Publisher Copyright:
© 2016 by The American Society for Biochemistry and Molecular Biology, Inc.
PY - 2016/2/26
Y1 - 2016/2/26
N2 - PAX5 is a transcription factor that is required for the development and maintenance of B cells. Promyelocytic leukemia (PML) is a tumor suppressor and proapoptotic factor. The fusion gene PAX5-PML has been identified in acute lymphoblastic leukemia with chromosomal translocation t(9;15)(p13; q24). We have reported previously that PAX5-PML dominant negatively inhibited PAX5 transcriptional activity and impaired PML function bydisrupting PML nuclear bodies (NBs). Here we demonstrated the leukemogenicity of PAX5-PML by introducing it into normal mouse pro-B cells. Arrest of differentiation was observedin PAX5-PML-introduced pro-B cells, resulting in the development of acute lymphoblastic leukemia after a long latency in mice. Among the transactivation targets of PAX5, B cell linker protein (BLNK) was repressed selectively in leukemia cells, and enforced BLNK expression abrogated the differentiation block and survival induced by PAX5-PML, indicating the importance of BLNK repression for the formation of preleukemic state. We also showed that PML NBs were intactinleukemia cells and attributed this to the low expression of PAX5-PML, indicating that the disruption of PML NBs was not required for the PAX5-PML-induced onset of leukemia. These results provide novel insights into the molecular mechanisms underlying the onset of leukemia by PAX5 mutations.
AB - PAX5 is a transcription factor that is required for the development and maintenance of B cells. Promyelocytic leukemia (PML) is a tumor suppressor and proapoptotic factor. The fusion gene PAX5-PML has been identified in acute lymphoblastic leukemia with chromosomal translocation t(9;15)(p13; q24). We have reported previously that PAX5-PML dominant negatively inhibited PAX5 transcriptional activity and impaired PML function bydisrupting PML nuclear bodies (NBs). Here we demonstrated the leukemogenicity of PAX5-PML by introducing it into normal mouse pro-B cells. Arrest of differentiation was observedin PAX5-PML-introduced pro-B cells, resulting in the development of acute lymphoblastic leukemia after a long latency in mice. Among the transactivation targets of PAX5, B cell linker protein (BLNK) was repressed selectively in leukemia cells, and enforced BLNK expression abrogated the differentiation block and survival induced by PAX5-PML, indicating the importance of BLNK repression for the formation of preleukemic state. We also showed that PML NBs were intactinleukemia cells and attributed this to the low expression of PAX5-PML, indicating that the disruption of PML NBs was not required for the PAX5-PML-induced onset of leukemia. These results provide novel insights into the molecular mechanisms underlying the onset of leukemia by PAX5 mutations.
UR - http://www.scopus.com/inward/record.url?scp=84964584327&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84964584327&partnerID=8YFLogxK
U2 - 10.1074/jbc.M115.637835
DO - 10.1074/jbc.M115.637835
M3 - Article
C2 - 26703467
AN - SCOPUS:84964584327
SN - 0021-9258
VL - 291
SP - 4723
EP - 4731
JO - Journal of Biological Chemistry
JF - Journal of Biological Chemistry
IS - 9
ER -